Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
Mobility Impairment Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Clin Neurol Neurosurg. 2021 Apr;203:106549. doi: 10.1016/j.clineuro.2021.106549. Epub 2021 Feb 8.
Parkinson's disease is a progressive neurodegenerative disease and the second most common neurological disease in the world, which usually affects people mainly in later years of life. Cognitive impairments and depressive symptoms are important symptoms in these patients that are associated with a poor prognosis. The study will focus on the original data regarding the cognitive impairments and depressive symptoms in patients with Parkinson's disease and control group.
In a case-control study, a total of 100 Parkinson's patients who were hospitalized in Rouhani Hospital and 200 non-Parkinson's people (control group) from Amirkola Health and aging project (AHAP) Marras et al., Babol, Iran were enrolled between September 2019 to February 2020. Data were collected by simple random sampling. Data were collected using a four-part questionnaire, including demographic characteristics, Unified Parkinson Disease Rating Scale (UPDRS), Modified Hoehn and Yahr staging Scale (MHYSS), Mini-M ental State Examination (MMSE) and Geriatric Depression Scale (GDS). P-value less than 0.05 was considered as significant RESULTS: A total of 300 persons were enrolled in the study. The mean age of Parkinson's patients and non-Parkinson's people was 70.34 ± 7.76 and 70.87 ± 7.59 years, respectively. The mean MMSE score in Parkinson's and non-Parkinson's people was 24.80 ± 4.53 and 25.40 ± 3.1, respectively (p = 0.182). The mean GDS score in Parkinson's and non-Parkinson's people was 7.06 ± 4.06 and 4.31 ± 3.47, respectively (p = 0.001). There was a statistically significant relationship between depressive symptoms and cognitive impairments with disease severity (p = 0.022 and p = 0.012, respectively). In addition, variables, such as age and the education level were associated with cognitive impairments (p = 0.001 and p = 0.021, respectively), but these variables were not significantly associated with depressive symptoms (p = 0.843 and p = 0.411, respectively). There was a significant relationship between depressive symptoms and cognitive impairment in Parkinson's patients and the control group (p = 0.001 and p = 0.003, respectively).
Cognitive impairments and depressive symptoms were significantly associated with an increase in the severity of Parkinson's disease, and also, depressive symptoms in Parkinson's patients was associated with an increase in cognitive impairments.
帕金森病是一种进行性神经退行性疾病，是世界上第二常见的神经退行性疾病，通常主要影响晚年人群。认知障碍和抑郁症状是这些患者的重要症状，与预后不良有关。本研究将重点关注帕金森病患者和对照组的认知障碍和抑郁症状的原始数据。
在一项病例对照研究中，我们共纳入了 2019 年 9 月至 2020 年 2 月期间在鲁哈尼医院住院的 100 名帕金森病患者和来自伊朗马拉萨卜布尔的阿米科拉健康与老龄化项目（AHAP）的 200 名非帕金森病患者（对照组）。数据采用简单随机抽样法收集。数据采用四部分问卷收集，包括人口统计学特征、统一帕金森病评定量表（UPDRS）、改良 Hoehn 和 Yahr 分期量表（MHYSS）、简易精神状态检查（MMSE）和老年抑郁量表（GDS）。P 值小于 0.05 被认为具有统计学意义。
共有 300 人纳入研究。帕金森病患者和非帕金森病患者的平均年龄分别为 70.34±7.76 岁和 70.87±7.59 岁。帕金森病患者和非帕金森病患者的 MMSE 评分分别为 24.80±4.53 分和 25.40±3.1 分（P=0.182）。帕金森病患者和非帕金森病患者的 GDS 评分分别为 7.06±4.06 分和 4.31±3.47 分（P=0.001）。抑郁症状和认知障碍与疾病严重程度呈显著相关（P=0.022 和 P=0.012）。此外，年龄和教育水平等变量与认知障碍有关（P=0.001 和 P=0.021），但这些变量与抑郁症状无显著相关性（P=0.843 和 P=0.411）。帕金森病患者和对照组的抑郁症状和认知障碍之间存在显著关系（P=0.001 和 P=0.003）。
认知障碍和抑郁症状与帕金森病严重程度的增加显著相关，帕金森病患者的抑郁症状与认知障碍的增加也显著相关。
